Year: 2022

logo-pharma-essentia-1

PharmaEssentia Honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the Introduction of BESREMi® (ropeginterferon alfa-2b-njft) for Polycythemia Vera

propanc-logo-update

Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer

PRP to Attack the Final Frontier, Metastatic Cancer MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a...